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Abstract
CCL3 is a ligand for the HIV-1 co-receptor CCR5. There have recently been conflicting reports in the literature concerning
whether CCL3-like gene (CCL3L) copy number variation (CNV) is associated with resistance to HIV-1 acquisition and with both
viral load and disease progression following infection with HIV-1. An association has also been reported between CCL3L CNV
and clinical sequelae of the simian immunodeficiency virus (SIV) infection in vivo in rhesus monkeys. The present study was
initiated to explore the possibility of an association of CCL3L CNV with the control of virus replication and AIDS progression
in a carefully defined cohort of SIVmac251-infected, Indian-origin rhesus monkeys. Although we demonstrated extensive
variation in copy number of CCL3L in this cohort of monkeys, CCL3L CNV was not significantly associated with either peak or
set-point plasma SIV RNA levels in these monkeys when MHC class I allele Mamu-A*01 was included in the models or
progression to AIDS in these monkeys. With 66 monkeys in the study, there was adequate power for these tests if the
correlation of CCL3L and either peak or set-point plasma SIV RNA levels was 0.34 or 0.36, respectively. These findings call
into question the premise that CCL3L CNV is important in HIV/SIV pathogenesis.
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Introduction
Host genetic factors influence susceptibility to HIV-1 replication
and progression to AIDS. A number of genes in humans have
been shown to impact the development of classical immune
effector responses against HIV-1 infection and HIV-1 entry into
cells. The genes associated with immune control of HIV-1 include
selected MHC class I alleles, including HLA B*5701, HLA B*27
[1], HLA C alleles [2], and HLA Bw4-8OI in association with
KIR3DS1 [3]. Expression of the delta 32 allelic form of the HIV-1
co-receptor CCR5 is associated with an inhibition of HIV-1 entry
into cells [4–6].
CCL3, formerly known as macrophage inflammatory factor 1a
(MIP-1a), a ligand for CCR5, is a chemokine with profound HIV-
1 inhibitory activity [7–9]. The two functional genes coding for
CCL3, CCL3 and CCL3-like 1( CCL3L1), map to a narrow region
on human chromosome 17. While CCL3 exists as two copies per
diploid genome (pdg), CCL3L1 arose from CCL3 through
segmental duplication, and the copy number of CCL3L1 varies
among individuals as a consequence of unequal duplications
[10,11]. It has been suggested that more copies of a gene should
translate into more protein expression, and higher CCL3L1 copy
number has been correlated with enhanced CCL3 production
[11]. Several groups reported that a low CCL3L1 copy number is
associated with an increased risk of acquiring HIV-1 as well as
both high viral loads and rapid progression to AIDS following
infection [7,9]. However, a recent series of reports show no effect
of CCL3L1 CNV on HIV-1 infection, viral loads, or progression to
AIDS following infection [12–14].
CNV at the CCL3L loci exists in both chimpanzees and rhesus
monkeys [7,15]. Indeed, a link between CCL3L CNV and AIDS
susceptibility has recently been reported in rhesus monkeys
infected with SIV [15]. The present study was initiated to explore
the possibility of an association between CCL3L CNV and AIDS in
rhesus monkeys.
Results
This study was done to assess the effect of CCL3L CNV on viral
load and disease progression following SIVmac251 infection in
Indian-origin rhesus monkeys. We first conducted experiments to
standardize the technical approach for determining CCL3L copy
number for this study. We assessed whether CCL3L copy number
calculated from the CCL3L-derived signal in our qPCR assay
PLoS Genetics | www.plosgenetics.org 1 June 2010 | Volume 6 | Issue 6 | e1000997systematically increased or decreased according to the quantity of
input DNA as described by Urban et al. [12]. We evaluated the
copy number of CCL3L using 18 ng of input DNA by the qPCR
method described by Degenhardt et al. [15] and concurrently
evaluated CCL3L copy number using either 9 ng or 36 ng of input
DNA. We explored the reproducibility of this qPCR assay using
duplicates for each of 69 DNA samples in each of two separate
experiments and evaluating the percent difference (defined as the
difference between CCL3L copy numbers in the duplicates divided
by their average, called Vi) as described by Urban et al. [12].
Higher quantities of input DNA tended to be associated with
larger ranges of Vi (Figure 1A); the averages of Vi over all 69
samples and the two experiments were 5.591 (9 ng), 9.681 (18 ng),
and 7.725 (36 ng). Assessing the CCL3L copy number averaged
over the two duplicates, the copy numbers obtained by the two
separate experiments had greater Pearson correlations using 9 ng
than either 18 ng or 36 ng of input DNA (Figure 1B for related
regressions). Thus, the use of more concentrated DNA samples
was associated with greater variability between replicates.
We then looked at the average (of 4 numbers – duplicates from
the two experiments) of the CCL3L copy numbers and regressed
the experiments using 18 ng and 36 ng of input DNA on the
experiment using 9 ng of input DNA. We found that 18 ng of
input DNA underestimated in 14 (20.3%) and overestimated in 20
(29.0%) samples, and also found that 36 ng of input DNA
underestimated in 19 (27.5%), and overestimated in 28 (40.6%)
samples (Figure 1C). Therefore, we only used determinations of
CCL3L copy number generated from DNA samples diluted to 9 ng
in this study.
Then, to determine the accuracy of our qPCR assay, we
assessed the copy number of CCL3L in the reference A431 human
cell line. The A431 cell line has previously been shown to have two
copies of CCL3L1 and two copies of CCL3 pdg, for a total copy
number of four CCL3L [11]. We found that the A431 human cell
line had 4 CCL3L copies when 9 ng of input DNA was assessed.
However, CCL3L copy number appeared to be higher than 4
when 18 or 36 ng of input DNA input were assayed (Figure 1C).
Since we have previously shown that Indian-origin and
Chinese-origin rhesus monkeys differ substantially in their control
of SIVmac251 replication [16], we reasoned that studying genetic
determinants of SIVmac251 control in a combined population of
both Indian-origin and Chinese-origin rhesus monkeys might
introduce a bias into the results. We therefore chose to pursue the
present study to evaluate the association of CCL3L CNV with the
control of SIV replication and AIDS progression in a cohort of
SIVmac251-infected Indian-origin rhesus monkeys.
The expression of particular MHC class I alleles in Indian-
origin rhesus monkeys is associated with the efficient control of
SIV replication and the rate of disease progression following SIV
infection [17–19]. We also recently demonstrated a central role of
TRIM5 polymorphism in limiting the replication of SIVmac251
in a primate host [20]. Although MHC class I, TRIM5 and
CCL3L are located on different chromosomes, it is possible that
the alleles of these genes are correlated with each other. If that
were the case, a CCL3L copy number effect could be confounded
or masked by either MHC class I or TRIM5 alleles associated
with SIV control. In order to address this issue, we included the
expression of both the MHC class I allele Mamu-A*01 and specific
TRIM5 alleles in our analysis to assess the effect of CCL3L CNV
on the control of SIVmac251 replication in Indian-origin rhesus
monkeys.
We evaluated CCL3L CNV in 84 Indian-origin rhesus monkeys.
The distribution of CCL3L copy number in this cohort of rhesus
monkeys is shown in Figure 2A. We observed extensive variation
in CCL3L copy number in these animals, with a range of 7 to 19
copies pdg (median 10.539). Data are displayed three ways in
Figure 2A: combining all monkeys, dividing the monkeys into 2
cohorts, one Mamu-A*012 and the other Mamu-A*01+, and
dividing the monkeys into 2 cohorts, one of animals expressing
only TRIM5 alleles 1–5 and the other of animals expressing at least
1 TRIM5 allele of the groups 6–11 as previously described [20].
CCL3L copy number did not appear to be equally distributed in
subgroups defined by Mamu-A*01 and by TRIM5. Animals with
high CCL3L copy number were overpresented among the Mamu-
A*01+ monkeys (shift to the right in Figure 2A). Importantly, we
found that Mamu-A*01+ rhesus monkeys possessed a significantly
greater number of CCL3L gene copies than the Mamu-A*01-
rhesus monkeys (Mann-Whitney P=0.003). However, the expres-
sion of particular TRIM5 alleles was not significantly associated
with the CCL3L copy number in the same cohort of rhesus
monkeys (Figure 2B).
Using all of these findings to inform our experimental approach,
we evaluated associations of CCL3L CNV with the in vivo control of
SIVmac251 replication during the period of acute infection in a
cohort of Indian-origin rhesus monkeys following intravenous
infection with SIVmac251. Plasma virus RNA levels were assessed
on day 14, at the time of peak virus replication, and on day 70, at
the time of set-point virus replication following SIVmac251
infection. The peak and set-point plasma SIV RNA levels have
been shown to be predictors of disease progression in SIVmac251-
infected monkeys [21,22].
To evaluate the effects of CCL3L copy number (used as a
continuous variable), Mamu-A*0l, and TRIM5 alleles (both
evaluated as binary variables) separately, we first used single
covariate linear regressions of log plasma SIV RNA levels at both
peak and set-point. When considered individually, we found that
each of the three variables were associated with log peak plasma
SIV RNA levels, but Mamu-A*01 was by far the most significant
(P,0.0001 vs. 0.04 for each of the other two covariates; Table 1).
In the regressions for log set-point plasma SIV RNA levels, the
expression of specific TRIM5 alleles was the most significant single
covariate (P=0.001) and Mamu-A*01 was significant (P=0.04) but
CCL3L copy number was not significant (P=0.53).
When considering several covariates together in the linear
regressions, the effect of CCL3L copy number was not significantly
associated with log peak plasma SIV RNA levels in any model
containing Mamu-A*01 (Table 2). CCL3L copy number was
significant (P=0.02) in the model containing only TRIM5 alleles,
but that model had a much smaller R
2 than any model involving
Mamu-A*01. The effect of CCL3L copy number was not significant
Author Summary
Host genetic factors are important in determining why
some individuals maintain effective control of HIV-1
replication while others do not. Genes implicated in this
control include a number associated with the develop-
ment of classical immune effector responses against HIV-1
infection and others associated with viral entry. CCL3,
formerly known as macrophage inflammatory factor 1a
(MIP-1a), is a ligand for the HIV-1 co-receptor CCR5 and a
chemokine that inhibits HIV-1 replication. The present
study was undertaken to assess the effect of CCL3L copy
number on the control of virus replication and AIDS
progression in SIVmac251-infected, Indian-origin rhesus
monkeys. We found that CCL3L copy number varies in
rhesus monkeys. However, the copy number is not
predictive of SIVmac251 containment following infection.
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any combination of the other two covariates, Table 2).
This analysis suggests that CCL3L copy number could simply
serve as a surrogate for the expression of the MHC class I allele
Mamu-A*01 and the early virus control associated with high or low
CCL3L copy number might be consequence of that MHC class I
allele. Therefore, our results show that it is important to control for
MHC class I alleles or other factors that might be associated with
CCL3L copy number in the study.
For power calculations, we considered the residual (Res) log
plasma SIV RNA levels when Mamu-A*01 was in the model (i.e.,
for each animal, the difference between the observed viral load
and that predicted by Mamu-A*01). For the peak viral load
regressions, with 66 animals there is 80% power to detect as
significant the contribution of CCL3L to the model if the true
correlation between Res and CCL3L is at least 0.34. (For
comparison, the observed value of the Pearson correlation was
0.01). For the set-point viral load regressions, there is 80% power
to detect as significant the contribution of CCL3L copy number to
the model if the true correlation between Res and CCL3L copy
number is at least 0.36 (the observed value of the Pearson
correlation was 0.13).
We also divided the rhesus monkeys used in this study into four
separate groups according to the expression of Mamu-A*01 and
TRIM5 alleles by the monkeys as shown in Figure 3. There was a
significant difference in CCL3L copy number between these 4
groups (Kruskal-Wallis P=0.0017), primarily between Mamu-
A*01+ and Mamu-A*012. The effect of CCL3L copy number was
Figure 1. Intra-experiment reproducibility and inter-experiment variability in CCL3L copy-number determination. (A) Intra-experiment
reproducibility as determined using duplicates for each DNA sample from 84 rhesus monkeys. The results of two separate experiments are shown. (B)
Inter-experiment variability. CCL3L copy numbers were determined by real-time qPCR using different amounts of input DNA. Correlations between
the mean of the unrounded CCL3L copy number estimates from two separate experiments are shown. (C) Bubble plots showing the concordance
between rounded CCL3L copy number estimates determined using different amounts of input DNA. The precision of each assay was determined by
the rounded CCL3L copy number estimate of from reference sample, the A431 human cell line (black arrow).
doi:10.1371/journal.pgen.1000997.g001
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SIV RNA levels or log set-point plasma SIV RNA levels for most
of these subgroups. Only for the group of monkeys that expressed
Mamu-A*01 and one of TRIM5 alleles from the group of allele 6–
11 was the CCL3L copy number coefficient significant, but the
number of monkeys in that group was very small (n=3) (Table 3).
Figure 2. Distribution of CCL3L copy number in Indian-origin rhesus monkeys. Copy numbers of CCL3L genes were estimated using real-
time PCR in 84 Indian-origin rhesus monkeys. (A) Frequency distribution of CCL3L copy number. Data are displayed three ways; combining all
monkeys, dividing the monkeys into 2 cohorts: one Mamu-A*012 and the other Mamu-A*01+, or dividing the monkeys into 2 cohorts: one of animlas
expressing only TRIM5 alleles 1–5 and the other of animals expressing at least 1 TRIM5 allele of the groups 6–11. The mean, variance, standard
deviation (SD) and median of the copy number are shown. (B) Boxplots of CCL3L copy number in Mamu-A*012 and Mamu-A*01+ animals, and, in
one of animlas expressing only TRIM5 alleles 1–5 and the other of animals expressing at least 1 TRIM5 allele of the groups 6–11. The comparisons
were analyzed using the Mann-Whitney U test (two-tailed).
doi:10.1371/journal.pgen.1000997.g002
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CCL3L using a primer/probe set that does not differentiate
between CCL3 and CCL3L gene paralogs as described by
Degenhardt et al. could be subject to systematic biases. To address
this possibility, we designed an alternative primer set and probe
specific for CCL3-like gene 1 (CCL3L1) using the known rhesus
monkey genome sequence (NCBI Reference Sequence:
NW_001160084) and found that this primer set and probe are
unique for CCL3L1 by ‘‘blastn’’ analysis (http://www.ncbi.nlm.
nih.gov/BLAST/). We again observed extensive variation in
CCL3L1 copy number in a cohort of animals, with a range of 3 to
13 copies pdg (median 8.04) (Supplementary Figure 3 in Text S1).
Consistent with the results of CCL3L1 CNV, these results showed
that there was a significant difference (Mann-Whitney P=0.04) in
the CCL3L1 copy numbers between Mamu-A*012 and Mamu-
A*01+ rhesus monkeys. However, the association between
CCL3L1 copy number and either log peak or log set-point plasma
SIV RNA levels was not significant in linear regression analysis
(Supplementary Figure 4 in Text S1).
We also divided the monkeys into 2 groups according to
whether the monkey’s CCL3L copy number was ‘‘below’’ and
‘‘above’’ the median copy number (10.54) for the entire population
of 66 monkeys. To be sure that this comparison was not affected
by the expression of Mamu-A*01 or TRIM5 alleles in the two
CCL3L groups, we divided each group of monkeys into four
separate groups according to their expression of Mamu-A*01 (2 or
+) and TRIM5 alleles (6–11 or 1–5) as shown in Figure 4. In this
analysis we again found no evidence for an association of CCL3L
copy number with either peak or set-point plasma SIV RNA levels
(Figure 4).
Finally, we assessed whether CCL3L copy number groups
(Below, , median of 10.54, or Above, $ median) are associated
with the percent of monkeys dying by day 235 (the follow-up time
was chosen ahead of time; after 235 days some monkeys were
euthanized and some were used in other experiments) in 45
monkeys from 7 experiments. These percents were compared by
Fisher exact test using each covariate (Mamu-A*01, TRIM5 alleles
and CCL3L) separately. CCL3L groups were not significant
(P=0.33); however, Mamu-A*012 status was associated with
significantly more frequent death (P=0.04) as was TRIM5 alleles
6–11 (P=0.005 (Table 4). To be sure that the CCL3L comparison
was not affected by an imbalance of Mamu-A*012 status or
TRIM5 alleles 6–11 in the two CCL3L groups, we also did an exact
Table 1. Regressions with single covariates.
Trait Covariate n b R
2 P value
Plasma SIV RNA (Peak) MHC class I (A*01)6 6 20.646 0.256 ,0.0001
TRIM5 66 20.238 0.065 0.04
CCL3L copy number 66 20.052 0.065 0.04
Plasma SIV RNA (Set-
point)
MHC class I (A*01)6 2 20.760 0.066 0.04
TRIM5 62 20.941 0.183 0.001
CCL3L copy number 62 20.039 0.007 0.53
Estimated coefficient (b)a n dP values are reported for the MHC class I (A*01),
TRIM5 alleles and the CCL3L copy number. R
2 values represent the fraction of
variation in the plasma SIV RNA levels explained by the single covariate in the
model.
doi:10.1371/journal.pgen.1000997.t001
Table 2. Effect of CCL3L copy number in regressions with
several covariates.
Trait Covariate n b P value
Plasma SIV RNA (Peak) MHC class I (A*01) 66 0.0123 0.92
TRIM5 66 20.058 0.02
MHC class I (A*01)&TRIM5 66 20.007 0.78
Plasma SIV RNA (Set-
point)
MHC class I (A*01) 62 0.033 0.48
TRIM5 62 20.086 0.13
MHC class I (A*01)&TRIM5 62 20.087 0.54
Estimated coefficient (b)a n dP values are reported for the CCL3L copy number
after correcting for the expression of MHC class I (A*01)o rTRIM5 alleles or both.
doi:10.1371/journal.pgen.1000997.t002
Figure 3. Distribution of CCL3L copy number in a cohort of
Indian-rhesus monkeys. Rhesus monkeys are divided into 4 groups
according to their expression of Mamu-A*01 allele (A*012 and A*01+)
and selected TRIM5 alleles (TRIM5 1–5: one expressing only TRIM5 alleles
1–5, TRIM5 6–11: the other expressing only TRIM5 alleles 6–11).
doi:10.1371/journal.pgen.1000997.g003
Table 3. Comparison of the regression coefficient (b) values
and the significance of CCL3L copy number from rhesus
monkeys expressing various combinations of both Mamu-
A*01 and TRIM5 alleles.
Groups
Trait
MHC
class I TRIM5 n b P value
Plasma SIV RNA (Peak) A*012 6–11 24 20.024 0.50
A*012 1–5 32 0.025 0.55
A*01+ 6–11 3 20.121 0.05
A*01+ 1–5 7 0.066 0.58
Plasma SIV RNA (Set-
point)
A*012 6–11 23 20.144 0.09
A*012 1–5 29 20.009 0.96
A*01+ 6–11 3 0.073 0.39
A*01+ 1–5 7 0.166 0.28
b and P values are reported for the CCL3L copy number.
doi:10.1371/journal.pgen.1000997.t003
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Mamu-A*012 status (P=0.99) and on TRIM5 alleles (P=0.83).
There were too few death (especially among Mamu-A*01+
monkeys) to stratify on both Mamu-A*01 and on TRIM5 alleles
(Table 5).
Discussion
We demonstrated extensive variation in CCL3L copy number in
a cohort of SIVmac251-infected Indian-origin rhesus monkeys
using real-time qPCR. However, we also showed that CCL3L copy
number co-stratified in this cohort of monkeys with Mamu-A*01,
an MHC class I allele associated with SIVmac251 control. Thus,
Mamu-A*01+ rhesus monkeys possess a significantly greater
number of CCL3L gene copies than Mamu-A*012 rhesus monkeys.
These findings suggest that CCL3L copy number might simply
serve as a surrogate for the Mamu-A*01 allele and the association
of control of SIV/AIDS pathogenesis associated with high or low
CCL3L copy number reported by Degenhardt et al. might actually
be a consequence of the expression of that MHC class I allele.
Degenhardt et al. also suggested that CCL3L CNV underlies not
only a significant inter-individual variation in the rate of
progression to AIDS in rhesus monkeys, but also the differences
in the pathogenicity of SIVmac251 between Indian-origin and
Chinese-origin rhesus monkeys. Indian-origin and Chinese-origin
rhesus monkeys certainly differ substantially in their control of
SIVmac251 replication [20,23]. However, these differences in
control may be a consequence of other genetic factors. We
therefore chose to evaluate the association of CCL3L CNV with
the control of SIV replication and AIDS progression in a cohort of
SIVmac251-infected Indian-origin rhesus monkeys. Exploring a
possible association of CCL3L CNV with SIVmac251 control in
such a defined cohort of rhesus monkeys would eliminate a bias
that might be introduced into the results by the diverse genetic
factors that may exist in a combined population of rhesus monkey
subspecies.
There are a number of potential caveats associated with the
findings in the present study. Although more copies of the CCL3L
gene should translate into a higher level of CCL3L expression, we
did not explore whether CCL3L copy number influences CCL3L
Figure 4. Lack of association of CCL3L CNV with virus replication in Indian-origin rhesus monkeys following SIVmac251 infection.
The plasma SIV RNA levels were assessed on days 14 and 70 following challenge, representing peak and set-point plasma SIV RNA levels, respectively.
The monkeys were divided into 2 groups, one having CCL3L copy numbers below the median in this cohort of monkeys (black), and the other having
CCL3L copy numbers above the median (red). These two groups of rhesus monkeys were subdivided into four separate groups according to their
expression of Mamu-A*01 (2 or +) and TRIM5 alleles (6–11 or 1–5). The association of CCL3L groups with plasma SIV RNA levels was assessed. The
comparisons were analyzed using the Mann-Whitney U test (two-tailed).
doi:10.1371/journal.pgen.1000997.g004
Table 4. Analysis of the survival status on day 235 following SIVmac251 infection.
Status
Covariate Alive Dead (%) Estimated RR (95% CI) PF
MHC class I Mamu-A*012 23 12 (34) NE 0.04
Mamu-A*01+ 10 0 (0)
TRIM5 TRIM5 6–11 6 13 (68) 7.2 (1.6–33.8) 0.005
TRIM5 1–5 20 6 (23)
CCL3L copy number Below median (,10.54) 11 6 (35) 2.0 (0.4–9.4) 0.33
Above median ($10.54) 22 6 (21)
The results are reported as number of animals observed.
NE: Not estimable because of zero cells.
doi:10.1371/journal.pgen.1000997.t004
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isolated from these experimental animals. Moreover, we only
evaluated an association of CCL3L CNV with the clinical
consequences of infection by one SIV isolate (SIVmac251). Since
other SIV isolates may make use of a different array of co-
receptors to infect cells, it is possible that the consequences of
CCL3L copy number on SIV control may differ for different SIV
isolates [24]. Finally, the interaction between chemokines and
their receptors can be promiscuous; a single chemokine can bind
multiple receptors and a single receptor can bind to multiple
chemokines. CCR5 binds to multiple chemokine ligands as it
subserves its biologic functions. These include MIP-1b (CCL4) and
RANTES (CCL5). In humans, there are multiple CCL4L genes
[25]; whether a similar diversity of these genes exist in rhesus
monkeys and contribute to SIV pathogenesis either independently
of, or in association with CCL3L in monkeys is not known.
CCL3L expression level was implicated in the control of HIV-1
replication and AIDS progression in humans as reported by
Gonzalez et al. [7]. However, results from other recent studies
suggest that CCL3L copy number is not associated with HIV-1
acquisition, viral loads or progression to AIDS following infection
[12–14]. The present data are consistent with the latter findings,
suggesting that CCL3L CNV is not associated with primate
immunodeficiency virus containment following infection and,
therefore, is not consequential in HIV/SIV pathogenesis.
Materials and Methods
Isolation of genomic DNA
Genomic DNA was isolated from freshly isolated PBMCs of 84
Indian-origin rhesus monkeys (66 animals inoculated with SIVmac
and 18 uninfected animals) by using the QIAamp DNA kit
(Qiagen). This group of monkeys included 56 Mamu-A*012 and
28 Mamu-A*01+ animals. Isolated total DNA quality was verified
by average A260/A280 ratio of 1.84 (range1.77–1.98). These DNA
samples were then aliquoted and stored at 220uC until use. We
confirmed the integrity of selected stored DNA samples using gel
electrophoresis.
Oligonucleotide primers and probes for real-time PCR
The qPCR primer and probe sequences for CCL3L were as
described by Degenhardt et al. [16]. This primer set does not
distinguish between CCL3 and the CCL3-like gene paralogs;
therefore, CCL3 and its paralogs are referred to as CCL3L.
Estimation of CCL3L copy number using real-time PCR
We determined the gene copy number of rhesus monkey CCL3L
using the method of Degenhardt et al. [15] with a few
modifications. Briefly, qPCR was performed using the 7300
Real-Time PCR System (Applied Biosystems) detecting emitted
fluorescence as FAM from the probe detecting CCL3L and VIC
from the probe detecting the STAT6 gene during amplification.
The qPCR included primers and probes with the Taqman PCR
mastermix (Applied Biosystems). The amount of test DNA sample
added to each PCR reaction was between 9–36 ng. Cycling
conditions were: initial denaturation at 94uC for 2 min; followed
by 40 cycles of 15 sec denaturation at 94uC; and 1 min annealing/
extension at 60uC. The Stat6 gene was used as the internal control.
Real-time qPCR results were analyzed using the SDS v1.4.0
software package (Applied Biosystems).
Generation of standard curves of CT value
Seven serial 1:2 dilutions (50–0.78 ng) of genomic DNA from
A431 cells known to have two copies of CCL3 and CCL3L1 pdg
were used to generate standard of CT value against log DNA on
each PCR plate (96 wells) for STAT6 present two copies per pdg
and CCL3L. The values obtained for the target gene CCL3L in
rhesus monkeys and the normalizer gene, STAT6, were similar,
which makes STAT6 gene a good housekeeping standard to
estimate of the copy numbers of CCL3L in rhesus monkeys. The
square of the Pearson correlation coefficient (R
2) for a standard
curve of less than 99% was considered inadequate, and the
corresponding PCR plate of DNA samples were repeated. The
signal obtained for the test DNA samples always fell on the
standard curve range. In Supplementary Figure 1 in Text S1, we
reported the calibration curve for the A431 reference sample.
Absolute quantitation of CCL3L copy number based on
reference samples
To estimate the absolute CCL3L copy number for each sample
based on the real-time qPCR results as described by Degenhardt
et al., we used the same reference sample, the A431 human cell
line. The A431 cell line was shown to have two copies of CCL3L1
and two copies of CCL3 pdg, for a total copy number of four
CCL3L using the qPCR assay. We determined the absolute CCL3L
copy number in each sample by comparing qPCR results between
the experimental and the reference samples. For each qPCR,
triplicate wells were set up for STAT6 and CCL3L,C T was
determined, and converted into template quantity using standard
Table 5. Test of CCL3L copy number group stratified on other covariates.
Status
Covariate
CCL3L copy
number group Alive
Dead
(%)
Estimated
stratified RR
(95% CI)
Fisher Exact
stratified test
of RR
Test of
Homogeneity
of RR’s
MHC class I A*012 Below median (,10.54) 10 6 (38) 1.3 (0.3–6.6) 0.99 1.00
Above median ($10.54) 13 6 (32)
A*01+ Below median (,10.54) 1 0 (0)
Above median ($10.54) 9 0 (0)
TRIM5 6–11 Below median (,10.54) 2 3 (60) 1.5 (0.3–8.5) 0.83 0.46
Above median ($10.54) 4 10 (71)
1–5 Below median (,10.54) 8 4(33)
Above median ($10.54) 12 2(14)
doi:10.1371/journal.pgen.1000997.t005
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quantity across the replicates for CCL3L to the averaged template
quantity of STAT6, multiplied by four (the diploid copy number of
the A431 cell line including CCL3L1 and CCL3) or two,
respectively. The resulting number was then rounded to the
nearest integer value to estimate absolute copy number.
In vivo infection
Animals. Indian-origin rhesus monkeys used in the analysis
were maintained according to the guidelines of the NIH Guide to the
Care and Use of Laboratory Animals and the approval of the
Institutional Animal Care and Use Committee of Harvard
Medical School and the National Institutes of Health. All
monkeys (n=66) used in this retrospective analysis were part of
9 different SIV research experiments. All animals were received
1 ml of a 1:3000 dilution of this stock by intravenous route.
Animals from 2 experiments (n=21) were excluded from the
results of survival status analysis since they were euthanized or
used in other experiments soon after day 70 (before any developed
AIDS-related illness).
Challenge virus. A stock of uncloned SIVmac251 was
expanded on human PBMC and titered in vivo in rhesus
monkeys for use in intravenous challenge studies [26].
Plasma viral RNA assay
Assays were performed using an ultrasensitive branched DNA
amplification assay (Bayer Diagnostics).
Statistical analysis
All statistical analyses were conducted using the XLSTAT
software (Addinsoft) and the StarXact 8 (Cytel) for Fisher exact
tests and stratified Fisher exact test, and nQuery Advisor 6.0
(Statistical Solutions) for power calculations for regression. The
log10 SIV RNA levels in plasma at the time of peak and set-point
were compared between groups by use of the exact Mann-
Whitney U test as was comparing CCL3L copy number between
Mamu-A*01 subgroups and between TRIM5 subgroups. The
Kruskal-Wallis test was used to compare CCL3L copy number
between 4 subgroups (divided by the expression of Mamu-A*01 and
TRIM5 alleles by the monkeys). Linear regressions of the log10
plasma SIV RNA at the time of peak and set-point were used
separately on each of three covariates (the binary variable Mamu-
A*01 and TRIM5 alleles and the continuous variable CCL3L copy
number) and also for models of two or three of these variables
together. Fisher exact tests were used to compare the percent of
monkeys that died by day 235 in various subgroups (defined by
CCL3L copy number being below or above the median observed
and by Mamu-A*01 and TRIM5 alleles). Exact estimated relative
risk (RR, similar to odds ratio but odds ratio can only be estimated
when the true prevalence is known) and 95% confidence intervals
(CIs) for RR were provided. Exact tests of association of CCL3L
copy number groups and the probability of dying by day 235
stratified by Mamu-A*01 and TRIM5 alleles and the related
stratified RR and test of homogeneity of RR used the method of
Zelen [27]. P values were two-tailed and considered significant
when ,0.05, no corrections for multiple comparisons were used.
Supporting Information
Text S1 Supplemental methods and figures.
Found at: doi:10.1371/journal.pgen.1000997.s001 (0.82 MB PDF)
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